selectION

selectION has established an efficient technology platform to develop highly selective peptide blockers for ion channels. Our most advanced candidate drug is si-544, a first-class Kv1.3 blocker used to treat effector memory T cell (T EM) driven diseases.The company is capable of expanding its leading range of ion channel blockers by targeting additional potassium, sodium, calcium, and chloride channels, which will lead to other clinical applications in pain management and oncology.